GPBAR1; | |
OPRD1; | |
PTPN1; PTPN2; ACP1; PTPN11; PTPRF; PTPN6; CDC25B; | |
CES1; RECQL; PLA2G1B; TDP1; HSD11B1; AKR1B10; HSD17B10; POLB; CES2; | |
GAA; ACHE; | |
AURKB; AURKA; KDR; | |
CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA4; CA6; | |
RORC; | |
NR1H4; | |
KDM4E; | |
MMP1; MMP12; MMP2; MMP9; | |
NFKB1; | |
ABCG2; | |
LMNA; RAB9A; MAPT; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
Enzyme_unclassified | CES1 | Acyl coenzyme A:cholesterol acyltransferase | P23141 | CHEMBL2265 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN6 | Protein-tyrosine phosphatase 1C | P29350 | CHEMBL3166 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 4.309E-12 | 1.043E-08 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP12, MMP2, MMP9, NR1H4, PTPN1, RORC |
BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 4.645E-09 | 7.225E-06 | ACP1, CDC25B, PTPN1, PTPN11, PTPN2, PTPN6, PTPRF |
BP | GO:0009987; cellular process | GO:0060338; regulation of type I interferon-mediated signaling pathway | 9.712E-08 | 1.057E-04 | MMP12, PTPN1, PTPN11, PTPN2, PTPN6 |
MF | GO:0003824; catalytic activity | GO:0004726; non-membrane spanning protein tyrosine phosphatase activity | 7.995E-07 | 6.217E-04 | ACP1, PTPN11, PTPN2 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.012E-06 | 7.600E-04 | MMP1, MMP12, MMP2, MMP9, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.778E-27 | 1.911E-22 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 2.527E-06 | 1.720E-03 | AURKA, CA2, CA9, CYP1B1, LMNA, MAPT, MMP9, NFKB1, OPRD1, POLB, PTPN1, PTPN11, PTPRF, RECQL, TDP1 |
BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 5.979E-06 | 3.465E-03 | CA3, CES1, CYP1A1, CYP1B1, KDR, NFKB1, OPRD1, POLB |
BP | GO:0009987; cellular process | GO:0033277; abortive mitotic cell cycle | 6.047E-06 | 3.465E-03 | PTPN11, PTPN6 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.423E-06 | 3.586E-03 | MMP1, MMP12, MMP2, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.168E-06 | 4.642E-03 | CES1, CES2, CYP1A1, CYP1B1, RORC |
BP | GO:0065007; biological regulation | GO:0065008; regulation of biological quality | 1.796E-05 | 7.733E-03 | ABCG2, ACHE, AURKA, AURKB, CA12, CA2, CA7, CYP1A1, CYP1B1, GAA, HSD11B1, KDR, MAPT, NFKB1, NR1H4, OPRD1, PLA2G1B, POLB, PTPN11, PTPN2, PTPN6 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.811E-05 | 7.733E-03 | CA2, CA7 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.811E-05 | 7.733E-03 | GPBAR1, NR1H4 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.811E-05 | 7.733E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0047374; methylumbelliferyl-acetate deacetylase activity | 1.811E-05 | 7.733E-03 | CES1, CES2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 2.033E-05 | 8.513E-03 | MMP1, MMP12, MMP2, MMP9 |
BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 2.098E-05 | 8.621E-03 | AURKA, AURKB, CYP1B1, MAPT, MMP9, NFKB1, NR1H4, PTPN1, PTPN2, PTPN6, PTPRF, RAB9A |
BP | GO:0009987; cellular process | GO:1900076; regulation of cellular response to insulin stimulus | 2.293E-05 | 9.078E-03 | NR1H4, PTPN1, PTPN11, PTPN2 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.687E-20 | 5.103E-16 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.983E-19 | 3.476E-15 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.410E-26 | 6.059E-24 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.970E-05 | 1.663E-03 | PTPN1; PTPN6; ACP1; PTPRF |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.232E-04 | 3.025E-03 | MMP2; KDR; PTPN6; PTPN11; MMP9 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.297E-04 | 3.025E-03 | MMP1; MMP2; MMP9 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.350E-04 | 3.025E-03 | PTPN1; PTPN11; NFKB1; PTPRF |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.649E-04 | 6.811E-03 | HSD11B1; CYP1A1; CYP1B1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.172E-04 | 1.004E-02 | HSD11B1; CYP1A1; CYP1B1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.612E-04 | 1.004E-02 | CA2; NR1H4; ABCG2 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.127E-03 | 2.165E-02 | PLA2G1B; KDR; PTPN11; NFKB1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.006E-03 | 1.252E-02 | HSD11B1; CYP1A1; CYP1B1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.854E-03 | 2.459E-02 | MMP2; PTPN11; MMP9 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.550E-03 | 3.885E-02 | CYP1B1; MMP9; NFKB1; CDC25B |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 6.450E-03 | 4.013E-02 | PTPN6; PTPN11; PTPN2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 4.151E-03 | 3.321E-02 | CYP1A1; CYP1B1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.420E-03 | 4.013E-02 | CYP1A1; CYP1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.382E-03 | 1.548E-02 | CA2; CA4 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 2.351E-03 | 2.194E-02 | AKR1B10; GAA |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 5.458E-03 | 3.885E-02 | CES2; CES1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B; MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1; NFKB1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; CES1; MMP12 |
C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; PLA2G1B; MMP1 |
N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CES1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; AURKA |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MMP9; MMP2; KDR; KDR; KDR; AURKB; AURKA |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; ACHE |
NA: NA | Colour dead tissues | NA | PTPN1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; MAPT |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MMP12 |
NA: NA | Edema | NA | CA2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; KDR |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
NA: NA | Upper abdominal bloating | NA | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1 |
I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | CES1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; KDR |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
C00-D49: Neoplasms | Breast cancer | C50 | CA9; KDR; KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; MMP1 |
C00-D49: Neoplasms | Glioma | C71 | KDR |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
C00-D49: Neoplasms | Cancer | C00-C96 | CDC25B; CA1; CA9; MMP9; NFKB1; MMP2; KDR; ACHE; AURKA |
C00-D49: Neoplasms | AML | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; CES1 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | CES1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Liver cancer | C22 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; MMP12 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; CES1 |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |